Ashvattha Therapeutics
Madhuri Chattopadhyay is a highly experienced senior scientist currently serving at Ashvattha Therapeutics, Inc. as Senior Scientist II since November 2023. Prior experience includes roles as Scientist II at Engine Biosciences, focusing on program design and assay validation, and Sr. Scientist in Biology at Maze Therapeutics. Madhuri has demonstrated expertise in developing biochemical and cell-based assays for preclinical drug discovery across multiple therapeutic areas, including oncology and immuno-oncology, with a strong foundation in enzyme activity assays and neuron differentiation. Educational qualifications include a PhD from the University of California, Santa Cruz, a Master's in Bioorganic Chemistry from the University of Maryland, and an MS in Chemistry from the Indian Institute of Technology, Kharagpur.
Ashvattha Therapeutics
Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel hydroxyl dendrimer (HD) therapeutics (HDTs) to treat unmet medical needs in oncology, ophthalmology, and inflammatory diseases.